前往化源商城

87-72-9 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Shanghai Institute of Organic Chemistry 靶标:N/A
External ID: PDBbind-Kd for protein-ligand complexes
Protocol:
Comment:
PDBbind Data LinkAffinity_QuilifierKdPubMedProtein TargetProtein NameMMDBPDB
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1a1e=191743431A1E_Btyrosine kinase C-src734321A1E
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1a7c<=10096347001A7C_Aplasminogen activator inhibitor type 1977141A7C
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1adl=4.479292281ADL_Atrp rna-binding attenuation protein551471ADL
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1ado=189893201ADO_Afructose 1,6-bisphosphate aldolase68251ADO
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1af6=1500092993371AF6_A,1AF6_Bmaltoporin76121AF6
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1ag9=0.00194166021AG9_Aflavodoxin68271AG9
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1ahx=12076641221AHX_A,1AHX_Baspartate aminotransferase37691AHX
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1ahy=44076641221AHY_A,1AHY_Baspartate aminotransferase37681AHY
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1aj6=1.292453981AJ6_ADNA gyrase b552221AJ6
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1aj7=13591800691AJ7_L,1AJ7_Himmunoglobulin 48g7 germline fab65881AJ7
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1akq=7.9E-498742011AKQ_Aflavodoxin552431AKQ
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1akr=8.2E-496224921AKR_Aflavodoxin552441AKR
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1akt=0.003296224921AKT_Aflavodoxin552451AKT
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1aku=0.7461AKU_Aflavodoxin552461AKU
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1akv=2.6E-61AKV_Aflavodoxin552471AKV
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1akw=0.002696224921AKW_Aflavodoxin552481AKW
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1amw=2992303031AMW_Aheat shock protein 90552781AMW
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1ao0=1192715021AO0_A,1AO0_Bglutamine phosphoribosylpyrophosphate66001AO0
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1apb=1.5122046271APB_Aapolipoprotein553081APB
http://www.pdbbind.org.cn/quickpdb.asp?quickpdb=1aqi=2.489955241AQI_Aadenine-n6-dna-methyltransferase taqi51821AQI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-SARS-cytotox-48hr-p1-npc
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Dispense; 2 uL cells; white, 1536-well Greiner assay plate.
2; Incubate; 16 hr; 37 C, 5% CO2
3; Dispense; 23 nL; compounds in DMSO
4; Incubate; 1 hr; 37 C, 5% CO2
5; Dispense; 2 uL; media
6; Incubate; 48 hr; 37C, 5% CO2
7; Centrifuge; 10 sec; Blue Washer gentle centrifugation
8; Dispense; 4 uL; ATPLite reagent
9; Incubate; 5 min; room temperature
10; Read; Luminescence; ViewLux plate reader

NOTES (numbers refer to Sequence numbers above)
1. Seed 1000 Vero E6 cells (ATCC #CRL-1586) in 2 uL/well media (EMEM 10% FetalClone II, 1x Pen/Strep) in white 1536-well assay plates (Greiner #782073).
2. Incubate at 37 C with 5% CO2 overnight (~16 h).
3. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubate for 1 hr at 37C 5% CO2.
5. Dispense 2 uL/well of media (EMEM 10% FetalClone II, 1x Pen/Strep).
6. Incubate at for 48 hr at 37C 5% CO2.
7. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
8. Dispense 4 uL/well of ATPLite 1step luminescence assay reagent (PerkinElmer #6016739).
9.Incubate for 5 min at room temperature.
10. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing cells as 100%, and wells containing media as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed apparent activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.104 uMActivity at 0.151 uMActivity at 0.229 uMActivity at 0.457 uMActivity at 0.573 uMActivity at 0.907 uMActivity at 1.145 uMActivity at 2.290 uMActivity at 3.065 uMActivity at 5.336 uMActivity at 6.860 uMActivity at 11.40 uMActivity at 15.33 uMActivity at 26.44 uMActivity at 34.30 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.5 uMActivity at 171.0 uMCompound QC
Inactive0004-4.2348000-4.2348QC'd by SIGMA
Inactive000400000QC'd by SIGMA
Inactive000400000QC'd by FLUKA
Inactive00040.2955-8.4544-0.071900.2955QC'd by SigmaAldrich
Inactive0-4.354.95490.7922-9.23891.540 0 0 0-6.8657004.5852-6.8657QC'd by SIGMA
Inactive00041.8364002.721.8364QC'd by Labotest
Inactive00041.8575004.55181.8575QC'd by SigmaAldrich
Inactive0004-1.7790-6.65020-1.779QC'd by SigmaAldrich
Cytotoxic5.623496.191184Complete curve; high efficacy-5.254.95490.9999-95.69110.5-1.10 0 0 0-96.07540.19610-92.9298-96.0754QC'd by Specs
Cytotoxic5.623490.58383Complete curve; high efficacy-5.254.95490.9987-88.5832-1.10 0 0 0-87.879903.2013-86.768-87.8799QC'd by Vitas
Cytotoxic0.707938.616166Complete curve; partial efficacy-6.153.990.9995-74.868-36.2519-1.20 0 0 0-75.3228-41.8999-74.8595-74.5922-75.3228QC'd by Sequoia
Cytotoxic3.5481102.204145Partial curve; high efficacy-5.454.50450.9986-99.70412.5-2.10 0 0 0-99.505104.1801-25.022-99.5051QC'd by SIGMA
Cytotoxic8.912582.729443Partial curve; high efficacy-5.051.55790.9999-91.2905-8.5611-2.10 0 0 0-87.443-9.2176-17.4332-57.2315-87.443QC'd by SigmaAldrich
Cytotoxic7.943395.366643Partial curve; high efficacy-5.11.34430.9999-95.7901-0.4234-2.10 0 0 0-89.19-2.0195-15.8041-59.401-89.19QC'd by Bosche
Cytotoxic14.125499.693742Partial curve; high efficacy-4.852.72020.9996-98.69371-2.10 0 0 0-96.758501.5165-34.3212-96.7585QC'd by NCI
Cytotoxic1095.453642Partial curve; high efficacy-53.92950.9998-96.4536-1-2.10 0 0 0-96.26110-1.9942-60.9288-96.2611QC'd by Microsource
Cytotoxic1063.467342Partial curve; partial efficacy-53.1320.9999-62.96730.5-2.20 0 0 0-62.690600-37.6527-62.6906QC'd by APExBIO
Cytotoxic8.912571.983342Partial curve; partial efficacy-5.054.0951-71.98330-2.20 0 0 0-71.915100-52.954-71.9151QC'd by Sequoia
Cytotoxic14.125483.876341Partial curve; partial efficacy-4.851.92820.9988-79.87634-2.20 0 0 0-74.88544.84030-28.1646-74.8854QC'd by Vitas
Cytotoxic22.3872106.157741Partial curve; high efficacy-4.652.24810.999-102.15774-2.10 0 0 0-90.56532.21854.8235-14.3188-90.5653QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: GPx1-biochemical-p4-p7
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent 1; 3 uL; GPx1 enzyme or no enzyme control in 1536-well, black, solid Greiner assay plate.
2; Compound; 25 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head.
3; Incubation; 30 min; room temperature.
4; Reagent 2; 1 uL; 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA substrate
5; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.
6; Incubation; 15 min; room temperature.
7; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.

NOTES (numbers refer to Sequence numbers above)
1. 3 uL of 16.66 nM GPX1 and 0.016% BSA in assay buffer (50 mM Tris-HCl, 2 mM EDTA (pH 7.5), 150 mM NaCl) was added to columns 3-48 of 1536-well assay plates using a BioRAPTR Flying Reagent Dispenser (Let's Go Robotics (LGR), Carlsbad, CA). A no-enzyme control (0.01% BSA in TES assay buffer) was added to columns 1-2.
2. 25 nL of test compounds and DMSO controls were added to each well with a pin tool (Kalypsys).
3. The assay plates were incubated for 30 minutes at room temperature.
4. 1 uL of master mix (500 nM glutathione reductase (GR), 5 mM reduced glutathione (GSH), 2.5 mM NADPH in assay buffer) was added. 1 uL of cumene hydroperoxide (CHP) ([2.5 mM] in 50% EtOH) was then added within 5 minutes to initiate the reaction. Final concentrations were: 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA.
5. Initial fluorescence readout (t=0) at 340/450 nm was measured using a ViewLux multimodal detector (PerkinElmer, Waltham, MA).
7. Endpoint fluorescence readout (t=15) at 340/450 nm was measured 15 min after room temperature incubation.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000080000 uMActivity at 0.0000294000 uMActivity at 0.0000322389 uMActivity at 0.0000640000 uMActivity at 0.0001602685 uMActivity at 0.0003305803 uMActivity at 0.0007029698 uMActivity at 0.00145 uMActivity at 0.00305 uMActivity at 0.00484 uMActivity at 0.00883 uMActivity at 0.016 uMActivity at 0.036 uMActivity at 0.076 uMActivity at 0.127 uMActivity at 0.227 uMActivity at 0.400 uMActivity at 1.089 uMActivity at 1.958 uMActivity at 4.491 uMActivity at 9.517 uMActivity at 15.29 uMActivity at 27.66 uMActivity at 48.83 uMActivity at 98.28 uMActivity at 150.0 uMCompound QC
Inhibitor1.153584.01186Complete curve; high efficacy-5.9382.95230.9935-85.511-1.5-1.10 0 0 0 0 0 1000.55170-10.1942-66.3862-86.37470QC'd by MedChem Express
Inhibitor4.0381107.130985Complete curve; high efficacy-5.39381.10.9833-107.6309-0.5-1.10 0 0 0 0 0 0-99.10763.0643-3.35612.7295-17.6643-28.702-81.8703-99.1076QC'd by Prestwick
Inhibitor4.5309100.661985Complete curve; high efficacy-5.34381.46410.9928-111.2365-10.5746-1.10 0 0 0 0 0 0-102.4277-6.7289-14.1368-11.7774-11.5064-34.358-88.9997-102.4277QC'd by Glixx
Inhibitor3.207694.995685Complete curve; high efficacy-5.49381.69240.997-110.0264-15.0308-1.10 0 0 0 0 0 0-108.5073-10.859-15.7072-17.8113-19.7979-44.1871-99.3353-108.5073QC'd by MedChem Express
Inhibitor3.207694.333585Complete curve; high efficacy-5.49381.55790.9917-98.6297-4.2962-1.10 0 0 0 0 0 0-97.268-10.9671-0.2469-8.8219-8.6028-35.074-85.0291-97.268QC'd by Vitas
Inhibitor4.0381101.224485Complete curve; high efficacy-5.39382.24810.9999-101.22440-1.10 0 0 0 0 0 0-101.0224000.6663-1.57-17.0563-89.6716-101.0224QC'd by DC Chemicals
Inhibitor4.5309102.529384Complete curve; high efficacy-5.34381.88510.9958-104.0293-1.5-1.10 0 0 0 0 0 0-100.803500-6.96670.0183-19.6985-87.3271-100.8035QC'd by MedChem Express
Inhibitor5.152590.153784Complete curve; high efficacy-5.2881.96730.9895-98.5024-8.3487-1.10 0 0 0 0 0 0-96.571-12.4368-8.9031-14.8602-3.6239-19.2852-77.5914-96.571QC'd by EMD Chemicals
Inhibitor6.496.476183Complete curve; high efficacy-5.19383.92950.9988-94.97611.5-1.10 0 0 0 0 0 0-95.357503.3535002.0026-79.8012-95.3575QC'd by Microsource
Inhibitor6.489.09983Complete curve; high efficacy-5.19384.44950.9997-88.5990.5-1.10 0 0 0 0 0 0-88.422200.5042.224300-77.8921-88.4222QC'd by SigmaAldrich
Inhibitor4.0928572.588765Partial curve; high efficacy-5.3882.90231-572.58870-2.10 0 0 0 0 0 100000-52.3008-521.48330QC'd by Microsource
Inhibitor2.547977.642365Complete curve; partial efficacy-5.59384.50450.9919-92.3162-14.6738-1.20 0 0 0 0 0 0-90.5524-12.7147-12.5699-11.8115-21.2763-34.6101-93.8172-90.5524QC'd by SIGMA
Inhibitor2.023979.203365Complete curve; partial efficacy-5.69381.1110.9975-92.0986-12.8952-1.20 0 0 0 0 0 0-89.2428-13.3008-14.4831-11.996-25.7417-51.5286-82.1843-89.2428QC'd by SIGMA
Inhibitor2.547939.753164Complete curve; partial efficacy-5.59384.50450.9617-72.8813-33.1282-1.20 0 0 0 0 0 0-68.5285-37.2443-35.4912-31.4131-28.8568-43.7703-77.3346-68.5285QC'd by Microsource
Inhibitor5.7812259.6350Partial curve; high efficacy-5.2381.69240.9999-259.630-2.10 0 0 0 0 0 0-250.1252000-1.0316-34.0768-179.1962-250.1252QC'd by Adooq
Inhibitor4.0928222.462650Partial curve; high efficacy-5.3882.58840.9995-221.46261-2.10 0 0 0 0 0 100003.8047-24.8352-196.33210QC'd by Glixx
Inhibitor18.0377742.537649Partial curve; high efficacy-4.74382.72021-741.53761-2.10 0 0 0 0 0 0-698.2464003.833500-124.2034-698.2464QC'd by Vitas
Inhibitor16.0761622.503649Partial curve; high efficacy-4.79382.25261-622.50360-2.10 0 0 0 0 0 0-576.39220000-5.8017-157.3588-576.3922QC'd by Glixx
Inhibitor16.0761415.830746Partial curve; high efficacy-4.79382.25260.9995-418.3307-2.5-2.10 0 0 0 0 0 0-387.3433-6.004500-3.7575-3.0222-113.565-387.3433QC'd by SIGMA
Inhibitor16.2936426.190146Partial curve; high efficacy-4.7882.72020.9998-425.69010.5-2.10 0 0 0 0 0 0-400.838100003.5739-74.4409-400.8381QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-MERS-PP-p1-npc
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Dispense; 2 uL cells; white, 1536-well Greiner assay plate.
2; Incubate; 16 hr; 37C, 5% CO2
3; Dispense; 23 nL; compounds in DMSO
4; Incubate; 1 hr; 37C, 5% CO2
5; Dispense; 2 uL; SARS-S MLVpp
6; Centrifuge; 45 min; 1500 rpm, room temperature
7; Incubate; 48 hr; 37C, 5% CO2
8; Centrifuge; 10 sec; Blue Washer gentle centrifugation
9; Dispense; 4 uL; Bright-Glo Luciferase reagent
10; Incubate; 5 min; room temperature
11; Read; Luminescence; ViewLux plate reader

NOTES (numbers refer to Sequence numbers above)
1. Seed 2000 Huh7 cells (JCRB cell bank # JCRB0403) in 2 microL/well media (DMEM 10% FetalClone II, 1x Pen/Strep) in white 1536-well assay plates (Greiner #782073).
2. Incubate at 37 degrees C with 5% CO2 overnight (~16 h).
3. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubate for 1 h at 37C 5% CO2.
5. Dispense 2 microL/well of MERS-S pseudotyped particles (MERS-S MLVpp).
6. Spin-inoculate by centrifugation at 1500 rpm (453 xg) for 45 min at room temperature.
7. Incubate at for 48 h at 37C 5% CO2.
8. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
9. Dispense 4 microL/well of Bright-Glo Luciferase detection reagent (Cat#E2620, Promega).
10. Incubate for 5 min at room temperature.
11. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing MERS-S MLVpp as 100%, and wells containing control MLVpp (no fusion protein) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.104 uMActivity at 0.151 uMActivity at 0.229 uMActivity at 0.457 uMActivity at 0.573 uMActivity at 0.907 uMActivity at 1.145 uMActivity at 2.290 uMActivity at 3.065 uMActivity at 5.336 uMActivity at 6.860 uMActivity at 11.40 uMActivity at 15.33 uMActivity at 26.44 uMActivity at 34.30 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.5 uMActivity at 171.0 uMCompound QC
Inhibitor196.333987Complete curve; high efficacy-64.95490.9998-94.33392-1.10 0 0 0-94.71280-92.7751-93.4163-94.7128QC'd by Labotest
Inhibitor0.891383.712687Complete curve; high efficacy-6.052.78680.9996-96.241-12.5283-1.10 0 0 0-96.6275-23.7736-90.8469-95.0049-96.6275QC'd by Microsource
Inhibitor1.258996.405987Complete curve; high efficacy-5.93.67720.9999-94.40592-1.10 0 0 0-94.7850-85.1427-94.1736-94.785QC'd by MedChem Express
Inhibitor1.995395.447386Complete curve; high efficacy-5.73.1321-95.44730-1.10 0 0 0-95.25680-13.739-92.0399-95.2568QC'd by Vitas
Inhibitor3.548197.463985Complete curve; high efficacy-5.454.0950.9999-96.96390.5-1.10 0 0 0-96.77030-13.1147-96.7363-96.7703QC'd by Vitas
Inhibitor2.511983.527785Complete curve; high efficacy-5.62.04790.9986-97.9692-14.4414-1.10 0 0 0-97.1916-15.3679-54.1106-93.8954-97.1916QC'd by Selleck
Inhibitor3.548195.216485Complete curve; high efficacy-5.451.34430.9998-100.6043-5.3878-1.10 0 0 0-99.2152-11.1565-39.2196-83.7948-99.2152QC'd by Microsource
Inhibitor5.623495.304384Complete curve; high efficacy-5.254.95490.9998-94.80430.5-1.10 0 0 0-94.05190.12070-92.6695-94.0519QC'd by NCI
Inhibitor4.466884.504484Complete curve; high efficacy-5.351.28760.9998-86.2923-1.788-1.10 0 0 0-82.6781-5.6567-27.5762-66.8514-82.6781QC'd by Microsource
Inhibitor5.623494.308284Complete curve; high efficacy-5.254.95490.9999-93.80820.5-1.10 0 0 0-93.620900-91.0139-93.6209QC'd by Microsource
Inhibitor5.011995.787984Complete curve; high efficacy-5.34.95490.9998-94.78791-1.10 0 0 0-94.598700-93.6402-94.5987QC'd by Microsource
Inhibitor7.079597.850183Complete curve; high efficacy-5.154.50450.9989-95.85012-1.10 0 0 0-96.23503.6521-85.6349-96.235QC'd by SigmaAldrich
Inhibitor7.0795100.26783Complete curve; high efficacy-5.154.95490.9991-98.7671.5-1.10 0 0 0-97.983103.2082-91.1572-97.9831QC'd by Vitas
Inhibitor8.912593.906183Complete curve; high efficacy-5.054.95490.9997-93.90610-1.10 0 0 0-93.160800-73.8376-93.1608QC'd by Prestwick
Inhibitor7.943389.629783Complete curve; high efficacy-5.14.50451-89.62970-1.10 0 0 0-89.450800-75.1088-89.4508QC'd by Microsource
Inhibitor0.794367.818568Complete curve; partial efficacy-6.11.62590.9992-98.2669-30.4484-1.20 0 0 0-98.6616-49.9386-88.086-96.3968-98.6616QC'd by Selleck
Inhibitor0.891367.063767Complete curve; partial efficacy-6.053.51170.9999-94.9798-27.9161-1.20 0 0 0-95.3612-33.7668-92.536-94.9745-95.3612QC'd by SIGMA
Inhibitor0.891374.058867Complete curve; partial efficacy-6.052.78680.9997-93.5396-19.4808-1.20 0 0 0-94.4845-29.5673-88.416-93.2736-94.4845QC'd by MedChem Express
Inhibitor2.818472.588465Complete curve; partial efficacy-5.552.40640.9994-99.8255-27.2371-1.20 0 0 0-99.0333-28.5309-54.1516-98.53-99.0333QC'd by GVK
Inhibitor3.548147.271765Complete curve; partial efficacy-5.452.12110.9998-98.6785-51.4068-1.20 0 0 0-98.4816-51.7655-65.2319-95.3281-98.4816QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-SARS-CoV-2-cytotox-48hr
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1. Cells. Seed 1500 HEK293-ACE2 cells (Expi293F with stable expression of human ACE2) in 2 uL/well media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin) in white 1536-well assay plates (Greiner #782073).
2. Incubation. Incubate at 37 C with 5% CO2 overnight (~16 h).
3. Compounds. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubation. Incubate for 1 h at 37C 5% CO2.
5. Reagent. Dispense 2 uL/well of media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin).
6. Incubation. Incubate at for 48h at 37C 5% CO2
7. Reagent. Dispense 4 uL/well of ATPLite 1step luminescence assay reagent (PerkinElmer #6016739).
8. Incubation. Incubate for 15 min at room temperature.
9. Detection. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing cells as 100%, and wells without cells (media only control) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.00705 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.070 uMActivity at 0.104 uMActivity at 0.147 uMActivity at 0.228 uMActivity at 0.454 uMActivity at 0.702 uMActivity at 0.990 uMActivity at 1.179 uMActivity at 2.205 uMActivity at 3.547 uMActivity at 5.245 uMActivity at 6.528 uMActivity at 11.35 uMActivity at 18.98 uMActivity at 27.12 uMActivity at 37.89 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.4 uMActivity at 171.0 uMCompound QC
Cytotoxic2.511989.96385Complete curve; high efficacy-5.62.40640.9988-81.9638-1.10 0 0 0-81.02564.3424-26.1944-82.8623-81.0256QC'd by MedChem Express
Cytotoxic3.162394.537785Complete curve; high efficacy-5.54.50450.9999-94.32250.2153-1.10 0 0 0-94.7013-0.2373-13.1526-93.6408-94.7013QC'd by SIGMA
Cytotoxic2.818494.81785Complete curve; high efficacy-5.552.04790.9999-95.8221-1.005-1.10 0 0 0-95.0616-6.2542-35.3146-94.5292-95.0616QC'd by APExBIO
Cytotoxic2.818490.520785Complete curve; high efficacy-5.553.06540.9989-88.52072-1.10 0 0 0-86.88350-24.056-89.9601-86.8835QC'd by MedChem Express
Cytotoxic5.623496.974284Complete curve; high efficacy-5.254.0951-95.47421.5-1.10 0 0 0-95.85761.65590-94.7507-95.8576QC'd by SynKinase
Cytotoxic3.981196.100684Complete curve; high efficacy-5.44.50451-95.10061-1.10 0 0 0-94.91080.5692-4.2795-94.8159-94.9108QC'd by Tocris
Cytotoxic2.511977.656384Complete curve; high efficacy-5.62.04790.9997-80.7421-3.0858-1.10 0 0 0-80.0369-5.0715-39.0219-77.613-80.0369QC'd by Microsource
Cytotoxic7.943399.498683Complete curve; high efficacy-5.14.95490.9997-96.99862.5-1.10 0 0 0-96.8051.23063.5418-95.9316-96.805QC'd by MedChem Express
Cytotoxic7.079597.835883Complete curve; high efficacy-5.154.95490.9993-95.83582-1.10 0 0 0-95.644503.4249-95.1788-95.6445QC'd by Tocris
Cytotoxic7.079597.375183Complete curve; high efficacy-5.154.0951-97.37510-1.10 0 0 0-97.18070-0.6843-95.5282-97.1807QC'd by MedChem Express
Cytotoxic7.0795102.439983Complete curve; high efficacy-5.151.69240.9998-100.43992-1.10 0 0 0-96.76290-9.8984-85.0051-96.7629QC'd by MedChem Express
Cytotoxic7.079596.356883Complete curve; high efficacy-5.154.95491-96.35680-1.10 0 0 0-96.164400-95.5939-96.1644QC'd by MedChem Express
Cytotoxic7.079593.612783Complete curve; high efficacy-5.154.95491-93.61270-1.10 0 0 0-93.425800-92.8807-93.4258QC'd by MedChem Express
Cytotoxic8.912597.135783Complete curve; high efficacy-5.054.95491-97.13570-1.10 0 0 0-96.941800-94.9322-96.9418QC'd by APExBIO
Cytotoxic8.9125105.03483Complete curve; high efficacy-5.051.64360.9999-100.0345-1.10 0 0 0-94.72923.0536-3.9173-76.9038-94.7292QC'd by Glixx
Cytotoxic1091.303782Complete curve; high efficacy-52.18761-85.80375.5-1.10 0 0 0-84.12124.86462.5388-67.7158-84.1212QC'd by SIGMA
Cytotoxic1098.125282Complete curve; high efficacy-52.84730.9999-97.62520.5-1.10 0 0 0-96.850400-83.9555-96.8504QC'd by Cayman
Cytotoxic11.220293.877282Complete curve; high efficacy-4.952.40640.9998-92.87721-1.10 0 0 0-91.056100-72.1776-91.0561QC'd by Selleck
Cytotoxic0.891360.234867Complete curve; partial efficacy-6.053.51170.9985-93.1767-32.9418-1.20 0 0 0-93.5509-51.1212-90.8041-91.9137-93.5509QC'd by Selleck
Cytotoxic0.794356.680267Complete curve; partial efficacy-6.13.92950.9999-91.2497-34.5695-1.20 0 0 0-91.0675-40.2642-90.3425-90.8279-91.0675QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: TRND-MERS-cytotox-48hr-p1-npc
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Dispense; 2 uL cells; white, 1536-well Greiner assay plate.
2; Incubate; 16 hr; 37C, 5% CO2
3; Dispense; 23 nL; compounds in DMSO
4; Incubate; 1 hr; 37C, 5% CO2
5; Dispense; 2 uL; media
6; Incubate; 48 hr; 37C, 5% CO2
7; Centrifuge; 10 sec; Blue Washer gentle centrifugation
8; Dispense; 4 uL; ATPLite reagent
9; Incubate; 5 min; room temperature
10; Read; Luminescence; ViewLux plate reader

NOTES (numbers refer to Sequence numbers above)
1. Seed 2000 Huh7 cells (JCRB cell bank # JCRB0403) in 2 uL/well media (DMEM 10% FetalClone II, 1x Pen/Strep) in white 1536-well assay plates (Greiner #782073).
2. Incubate at 37C with 5% CO2 overnight (~16 h).
3. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubate for 1 hr at 37C 5% CO2.
5. Dispense 2 uL/well of media (DMEM 10% FetalClone II, 1x Pen/Strep).
6. Incubate at for 48 hr at 37C 5% CO2.
7. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
8. Dispense 4 uL/well of ATPLite 1step luminescence assay reagent (PerkinElmer #6016739).
9. Incubate for 5 min at room temperature.
10. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing cells as 100%, and wells containing media as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no apparent activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.104 uMActivity at 0.151 uMActivity at 0.229 uMActivity at 0.457 uMActivity at 0.573 uMActivity at 0.907 uMActivity at 1.145 uMActivity at 2.290 uMActivity at 3.065 uMActivity at 5.336 uMActivity at 6.860 uMActivity at 11.40 uMActivity at 15.33 uMActivity at 26.44 uMActivity at 34.30 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.5 uMActivity at 171.0 uMCompound QC
Cytotoxic3.162391.43685Complete curve; high efficacy-5.53.92950.9999-96.4465-5.0105-1.10 0 0 0-96.1361-4.5921-25.7892-96.254-96.1361QC'd by Labotest
Cytotoxic3.981195.751784Complete curve; high efficacy-5.44.50450.9999-95.75170-1.10 0 0 0-95.19320-7.5797-95.5606-95.1932QC'd by Microsource
Cytotoxic1.258940.731466Complete curve; partial efficacy-5.91.210.9997-86.599-45.8676-1.20 0 0 0-85.9117-55.1995-73.2026-84.1817-85.9117QC'd by Enzo
Cytotoxic8.912598.06743Partial curve; high efficacy-5.053.06540.9999-97.5670.5-2.10 0 0 0-95.094600.6077-19.7721-95.0946QC'd by Tocris
Cytotoxic10105.244942Partial curve; high efficacy-51.13410.9999-99.74495.5-2.10 0 0 0-87.03751.9925-11.2908-50.5231-87.0375QC'd by SigmaAldrich
Cytotoxic7.079574.189742Partial curve; partial efficacy-5.151.210.9998-75.7999-1.6102-2.20 0 0 0-69.9242-3.8419-17.0574-49.2901-69.9242QC'd by Sequoia
Cytotoxic1082.250142Partial curve; high efficacy-52.78680.9996-81.25011-2.10 0 0 0-80.921200-46.8123-80.9212QC'd by Bosche
Cytotoxic11.220270.751442Partial curve; partial efficacy-4.953.1320.9997-70.75140-2.20 0 0 0-69.677300-36.9652-69.6773QC'd by Vitas
Cytotoxic11.220267.55142Partial curve; partial efficacy-4.952.40640.9997-67.5510-2.20 0 0 0-65.83420-1.4108-35.2917-65.8342QC'd by Sequoia
Cytotoxic7.943373.080642Partial curve; partial efficacy-5.11.22210.9998-71.08062-2.20 0 0 0-64.74650-11.4632-42.9379-64.7465QC'd by Microsource
Cytotoxic22.387277.777441Partial curve; partial efficacy-4.652.12111-77.77740-2.20 0 0 0-68.3920-0.4599-15.1027-68.392QC'd by Enzo
Cytotoxic12.589369.025841Partial curve; partial efficacy-4.91.98870.9999-66.02583-2.20 0 0 0-62.98692.81820.7552-27.7994-62.9869QC'd by Microsource
Cytotoxic19.952672.771641Partial curve; partial efficacy-4.72.04790.9998-72.27160.5-2.20 0 0 0-64.599700-16.6801-64.5997QC'd by Prestwick
Cytotoxic28.1838115.995140Partial curve; high efficacy-4.552.24810.9999-115.49510.5-2.10 0 0 0-95.767100-12.122-95.7671QC'd by Sequoia
Cytotoxic31.622866.021240Partial curve; partial efficacy-4.54.95490.9998-66.02120-2.20 0 0 0-65.808100-10.4112-65.8081QC'd by AKos
Cytotoxic28.1838106.765440Partial curve; high efficacy-4.552.24811-106.76540-2.10 0 0 0-88.528500-12.0122-88.5285QC'd by Toronto Research
Cytotoxic31.6228126.820340Partial curve; high efficacy-4.52.04371-126.32030.5-2.10 0 0 0-97.02020.59490-13.8992-97.0202QC'd by Selleck
Cytotoxic2.511946.556323Complete curve; partial efficacy-5.61.13410.9987-46.40310.1532-1.20 0 0 0-45.0904-4.8723-22.5413-38.9308-45.0904QC'd by Sequoia
Cytotoxic2.238743.954323Complete curve; partial efficacy-5.651.41630.9994-48.3722-4.4179-1.20 0 0 0-48.5721-8.6816-27.0016-44.0154-48.5721QC'd by Vitas
Cytotoxic1.258951.932623Complete curve; partial efficacy-5.92.63840.9993-48.43263.5-1.20 0 0 0-49.01170-39.4678-47.3958-49.0117QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: TRND-SARS-CoV-2-PP
Protocol: PROTOCOL TABLE (format as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.

1. Cells. Seed 1500 HEK293-ACE2 cells (Expi293F with stable expression of human ACE2) in 2 uL/well media (DMEM, 10% FBS, 1x L-glutamine, 1x Pen/Strep, 1 ug/ml puromycin) in white 1536-well assay plates (Greiner #782073).
2. Incubation. Incubate at 37C with 5% CO2 overnight (~16 h).
3. Compounds. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubation. Incubate for 1 hr at 37C 5% CO2.
5. Reagent. Dispense 2 uL/well of SARS-CoV-2-S pseudotyped particles. [a] PPs are produced with murine leukemia virus pseudotyping. [b] SARS-CoV-2-S is Wuhan-Hu-1 sequence (BEI #NR-52420) with C-terminal 19 amino acid truncation.
6. Centrifuge. Spin-inoculate by centrifugation at 1500 rpm (453 xg) for 45 min at room temperature.
7. Incubation. Incubate at for 48 hr at 37C 5% CO2
8. Centrifuge. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
9. Reagent. Dispense 4 uL/well of Bright-Glo Luciferase detection reagent (Promega #E2620).
10. Incubation. Incubate for 5 min at room temperature.
11. Detection. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing SARS-CoV-2-S PP as 100%, and wells containing bald PP (no fusion protein) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.00705 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.070 uMActivity at 0.104 uMActivity at 0.147 uMActivity at 0.228 uMActivity at 0.454 uMActivity at 0.702 uMActivity at 0.990 uMActivity at 1.179 uMActivity at 2.205 uMActivity at 3.547 uMActivity at 5.245 uMActivity at 6.528 uMActivity at 11.35 uMActivity at 18.98 uMActivity at 27.12 uMActivity at 37.89 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.4 uMActivity at 171.0 uMCompound QC
Inhibitor0.707934.828810Complete curve; partial efficacy; poor fit-6.154.95490.7525-34.81130.0174-1.40 0 0 0-43.6793-3.7355-37.8905-22.6342-43.6793QC'd by MedChem Express
Inhibitor35.481336.764810Single point of activity-4.452.40640.8748-40.7648-4-30 0 0 0-31.8873-11.45960-6.0521-31.8873QC'd by Pharmaron
Inhibitor39.810740.392710Single point of activity-4.44.44950.7948-48.5731-8.1804-30 0 0 0-41.7275-5.1127-20.8986-3.4837-41.7275QC'd by FLUKA
Inhibitor39.810736.302110Single point of activity-4.44.44950.9302-39.3021-3-30 0 0 0-33.1684-8.76590-0.1246-33.1684QC'd by Prestwick
Inhibitor1091.825410Partial curve; high efficacy; poor fit-53.92951-91.32540.5-2.31 0 0 0-91.1431-30.0380-57.0259-91.1431QC'd by APExBIO
Inhibitor39.810788.872610Single point of activity-4.44.95490.9981-87.87261-30 0 0 0-75.3105003.3645-75.3105QC'd by Microsource
Inhibitor39.810739.07410Single point of activity-4.44.95490.9982-38.5740.5-30 0 0 0-32.9783001.4313-32.9783QC'd by Carbosynth
Inhibitor17.782845.659310Partial curve; partial efficacy; poor fit-4.751.96730.9887-54.3257-8.6664-2.40 0 0 0-50.2467-11.0836-6.8054-21.6158-50.2467QC'd by TargetMol
Inhibitor39.810774.978610Single point of activity-4.44.44950.9815-77.9786-3-30 0 0 0-65.3989-8.931700-65.3989QC'd by MedChem Express
Inhibitor39.810735.78810Single point of activity-4.44.44950.945-39.8408-4.0529-30 0 0 0-34.034-8.1712-5.8755-0.0441-34.034QC'd by Adooq
Inhibitor19.952698.547510Partial curve; high efficacy; poor fit-4.71.96730.9936-101.5475-3-2.30 0 0 0-90.5058-6.67020-28.4282-90.5058QC'd by MedChem Express
Inhibitor39.810794.209610Partial curve; high efficacy; poor fit-4.44.44950.9731-106.3898-12.1802-2.30 0 0 0-90.4675-6.8168-21.693-10.2877-90.4675QC'd by Axon Medchem
Inhibitor39.810768.339410Single point of activity-4.44.95490.8933-61.33947-30 0 0 0-51.53290021.3412-51.5329QC'd by MedChem Express
Inhibitor11.220245.057510Partial curve; partial efficacy; poor fit-4.951.85790.9996-42.55752.5-2.41 0 0 0-40.794-21.67980-20.0057-40.794QC'd by MedChem Express
Inhibitor22.3872113.332310Partial curve; high efficacy; poor fit-4.651.69241-111.33232-2.31 0 0 0-91.8583-33.87930-25.3979-91.8583QC'd by Microsource
Inhibitor7.079544.4210Single point of activity-5.154.95490.6152-48.42-4-30 0 0 0-44.8333-14.7954-20.3760-44.8333QC'd by SIGMA
Inhibitor39.810732.918510Single point of activity-4.44.95490.6127-36.9185-4-30 0 0 0-32.01542.7163-20.08280-32.0154QC'd by Selleck
Inhibitor39.810751.184410Single point of activity-4.44.44951-51.18440-30 0 0 0-42.6537000-42.6537QC'd by MedChem Express
Inhibitor1058.179910Partial curve; partial efficacy; poor fit-53.51170.9887-59.1799-1-2.40 0 0 0-59.8069-4.87472.0564-35.7833-59.8069QC'd by DC Chemicals
Inhibitor39.810740.290110Single point of activity-4.44.44950.7334-45.6865-5.3964-30 0 0 0-38.9054-16.4277-13.0282-1.1636-38.9054QC'd by Adooq
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: TRND-SARS-PP-p1-npc
Protocol: Protocol:
PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Dispense; 2 uL cells; white, 1536-well Greiner assay plate.
2; Incubate; 16 hr; 37 C, 5% CO2
3; Dispense; 23 nL; compounds in DMSO
4; Incubate; 1 hr; 37 C, 5% CO2
5; Dispense; 2 uL; SARS-S MLVpp
6; Centrifuge; 45 min; 1500 rpm, room temperature
7; Incubate; 48 hr; 37C, 5% CO2
8; Centrifuge; 10 sec; Blue Washer gentle centrifugation
9; Dispense; 4 uL; Bright-Glo Luciferase reagent
10; Incubate; 5 min; room temperature
11; Read; Luminescence; ViewLux plate reader

NOTES (numbers refer to Sequence numbers above)
1. Seed 2000 Vero E6 cells (ATCC #CRL-1586) in 2 uL/well media (EMEM 10% FetalClone II, 1x Pen/Strep) in white 1536-well assay plates (Greiner #782073).
2. Incubate at 37 C with 5% CO2 overnight (~16 h).
3. Dispense 23 nL/well compounds in DMSO via pin transfer.
4. Incubate for 1 hr at 37C 5% CO2.
5. Dispense 2 uL/well of SARS-S pseudotyped particles (SARS-S MLVpp).
6. Spin-inoculate by centrifugation at 1500 rpm (453 xg) for 45 min at room temperature.
7. Incubate at for 48 hr at 37C 5% CO2.
8. Remove supernatant with gentle centrifugation using a Blue Washer (BlueCat Bio).
9. Dispense 4 uL/well of Bright-Glo Luciferase detection reagent (Promega #E2620).
10. Incubate for 5 min at room temperature.
11. Read luminescence signal (Viewlux plate reader, PerkinElmer). Data was normalized with wells containing SARS-S MLVpp as 100%, and wells containing control MLVpp (no fusion protein) as 0%.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.104 uMActivity at 0.151 uMActivity at 0.229 uMActivity at 0.457 uMActivity at 0.573 uMActivity at 0.907 uMActivity at 1.145 uMActivity at 2.290 uMActivity at 3.065 uMActivity at 5.336 uMActivity at 6.860 uMActivity at 11.40 uMActivity at 15.33 uMActivity at 26.44 uMActivity at 34.30 uMActivity at 57.10 uMActivity at 85.70 uMActivity at 114.5 uMActivity at 171.0 uMCompound QC
Inhibitor197.380287Complete curve; high efficacy-61.37230.9991-99.9438-2.5636-1.10 0 0 0-99.1506-27.553-75.0674-97.7163-99.1506QC'd by Microsource
Inhibitor1.412598.888487Complete curve; high efficacy-5.853.24750.9999-96.38842.5-1.10 0 0 0-96.77550-80.0472-95.8934-96.7755QC'd by Labotest
Inhibitor1.4125101.075287Complete curve; high efficacy-5.854.44950.9999-97.57523.5-1.10 0 0 0-97.96712.8759-86.7011-96.8007-97.9671QC'd by Labotest
Inhibitor1102.246387Complete curve; high efficacy-64.0950.9999-98.24634-1.10 0 0 0-98.64090-94.9201-97.3825-98.6409QC'd by Selleck
Inhibitor1100.87687Complete curve; high efficacy-62.04370.9997-97.58233.2937-1.10 0 0 0-97.9742-13.5052-82.6458-96.1026-97.9742QC'd by Microsource
Inhibitor2.238793.908186Complete curve; high efficacy-5.651.96730.9988-99.4111-5.503-1.10 0 0 0-98.0385-9.5858-51.8655-97.2234-98.0385QC'd by SIGMA
Inhibitor2.818497.821885Complete curve; high efficacy-5.552.72020.9992-96.82181-1.10 0 0 0-95.71360-33.6037-96.6286-95.7136QC'd by NCI
Inhibitor3.162382.273885Complete curve; high efficacy-5.52.84730.9999-99.8849-17.6111-1.10 0 0 0-99.6855-18.0092-40.9738-98.4052-99.6855QC'd by Vitas
Inhibitor3.548188.764685Complete curve; high efficacy-5.452.95230.9987-97.5643-8.7996-1.10 0 0 0-99.1507-8.1663-29.4656-93.2495-99.1507QC'd by Glixx
Inhibitor3.162399.786485Complete curve; high efficacy-5.52.47290.9993-99.78640-1.10 0 0 0-98.40860-32.3549-96.4346-98.4086QC'd by MedChem Express
Inhibitor3.548191.741984Complete curve; high efficacy-5.452.35310.9997-93.2919-1.55-1.10 0 0 0-93.6666-1.7084-26.6215-87.3985-93.6666QC'd by SIGMA
Inhibitor5.623498.837884Complete curve; high efficacy-5.254.95491-98.83780-1.10 0 0 0-98.64050-1.6294-96.1264-98.6405QC'd by Microsource
Inhibitor3.981197.129584Complete curve; high efficacy-5.44.50451-97.12950-1.10 0 0 0-97.51960-7.4315-96.036-97.5196QC'd by Microsource
Inhibitor0.891374.188768Complete curve; partial efficacy-6.053.19250.9999-97.3803-23.1916-1.20 0 0 0-97.7714-30.993-94.0197-96.8652-97.7714QC'd by ChemDiv
Inhibitor0.794377.951768Complete curve; partial efficacy-6.14.44950.9989-96.4651-18.5134-1.20 0 0 0-96.8525-24.5945-96.6992-94.6899-96.8525QC'd by SIGMA
Inhibitor0.891362.381668Complete curve; partial efficacy-6.053.1320.9999-97.0294-34.6478-1.20 0 0 0-97.4191-41.2998-94.2087-97.0954-97.4191QC'd by MedChem Express
Inhibitor3.162364.840865Complete curve; partial efficacy-5.53.24750.9993-96.5147-31.6739-1.20 0 0 0-95.2478-31.8116-48.6639-96.3221-95.2478QC'd by Prestwick
Inhibitor8.912596.79743Partial curve; high efficacy-5.054.0950.9999-96.7970-2.10 0 0 0-97.185800-70.4182-97.1858QC'd by Sequoia
Inhibitor12.589399.308542Partial curve; high efficacy-4.92.40640.9995-98.30851-2.10 0 0 0-96.380900-41.6052-96.3809QC'd by Tocris
Inhibitor14.125493.017342Partial curve; high efficacy-4.851.69240.9985-94.0173-1-2.10 0 0 0-87.0530-7.0161-38.4623-87.053QC'd by Microsource